Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis

Journal of Infectious Diseases

Volumn 208, Issue 9, 2013, Pages 1359-1365

  Van Velzen, Monique ^a   Van De Vijver, David A M C ^a   Van Loenen, Freek B ^a,b   Osterhaus, Albert D M E ^a   Remeijer, Lies ^b   Verjans, Georges M G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

acyclovir prophylaxis; acyclovir resistance; patients; recurrent keratitis; refractory disease; retrospective study; risk factors

Indexed keywords

ACICLOVIR;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; FEMALE; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; RISK FACTOR;

ACYCLOVIR PROPHYLAXIS; ACYCLOVIR RESISTANCE; PATIENTS; RECURRENT KERATITIS; REFRACTORY DISEASE; RETROSPECTIVE STUDY; RISK FACTORS;

ACYCLOVIR; AGED; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CHEMOPREVENTION; DRUG RESISTANCE, VIRAL; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; KERATITIS, HERPETIC; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; RISK FACTORS; VERO CELLS;

EID: 84885412966     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit350     Document Type: Article

References (35)

1. Roizman B, Knipe D, Whitley R. Herpes simplex viruses. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2007 (Knipe DM HP, eds, ed. Fields' virology
2. Remeijer L, Osterhaus AD, Verjans GM. Human herpes simplex virus keratitis: The pathogenesis revisited. Ocul Immunol Inflamm 2004; 12:255-85
3. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001; 20:1-13
4. Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea 2001; 20:123-8
5. Duan R, de Vries RD, van Dun JM, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200:1402-14
6. Frobert E, Cortay JC, Ooka T, et al. Genotypic detection of acyclovirresistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACVresistant viruses. Antiviral Res 2008; 79:28-36
7. Shin YK, Cai GY, Weinberg A, Leary JJ, Levin MJ. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol 2001; 39:913-7
8. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-Up. J Clin Microbiol 2004; 42:242-9
9. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459-72
10. Wilhelmus KR, Beck RW, Moke PS, et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998; 339: 300-6
11. Oral acyclovir for herpes simplex virus eye disease: Effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group. Arch Ophthalmol 2000; 118:1030-6
12. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008; 198:659-63
13. Sarisky RT, Bacon TH, Boon RJ, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 2003; 148:1757-69
14. Hillenaar T, van Cleynenbreugel H, Verjans GM, Wubbels RJ, Remeijer L. Monitoring the inflammatory process in herpetic stromal keratitis: The role of in vivo confocal microscopy. Ophthalmology 2012; 119:1102-10
15. Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2010; 12:CD002898
16. Sarisky RT, Nguyen TT, Duffy KE, Wittrock RJ, Leary JJ. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 2000; 44:1524-9
17. Hall JD, Coen DM, Fisher BL, et al. Generation of genetic diversity in herpes simplex virus: An antimutator phenotype maps to the DNA polymerase locus. Virology 1984; 132:26-37
18. Thi TN, Deback C, Malet I, Bonnafous P, Ait-Arkoub Z, Agut H. Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-Time PCR. Antiviral Res 2006; 69:152-7
19. Mertz GJ, Jones CC, Mills J, et al. Long-Term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 1988; 260:201-6
20. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or =6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169:1338-41
21. Shin YK, Weinberg A, Spruance S, et al. Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleosideresistant variants after repeated topical application of penciclovir to recurrent herpes labialis. J Infect Dis 2003; 187:1241-5
22. Kriesel JD, Spruance SL, Prichard M, Parker JN, Kern ER. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156-61
23. Nugier F, Colin JN, Aymard M, Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: Report on a two-year sensitivity screening survey. J Med Virol 1992; 36:1-12
24. Koelle DM, Corey L. Herpes simplex: Insights on pathogenesis and possible vaccines. Annu Rev Med 2008; 59:381-95
25. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007; 204:595-603
26. Niederkorn JY. Cornea: Window to ocular immunology. Curr Immunol Rev 2011; 7:328-35
27. Coen DM, Kosz-Vnenchak M, Jacobson JG, et al. Thymidine kinasenegative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 1989; 86:4736-40
28. Horsburgh BC, Chen SH, Hu A, Mulamba GB, Burns WH, Coen DM. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: Can strain differences compensate for loss of thymidine kinase in pathogenesis? J Infect Dis 1998; 178:618-25
29. Tenser RB, Ressel S, Dunstan ME. Herpes simplex virus thymidine kinase expression in trigeminal ganglion infection: Correlation of enzyme activity with ganglion virus titer and evidence of in vivo complementation. Virology 1981; 112:328-41
30. van Velzen M, van Loenen FB, Meesters RJ, et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 2012; 205:1539-43
31. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari TLok AS. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012; 19:205-12
32. Li JZ, Paredes R, Ribaudo HJ, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012; 26:185-92
33. Lairson DR, Begely CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: A cost-effectiveness analysis. Arch Ophthalmol 2003; 121:108-12
34. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-65
35. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60